Back to Results

Danaher Corporation (DHR)

Danaher Corporation is a diversified healthcare company listed on the NYSE under the ticker DHR. As a common stock issuer, it develops and commercializes products and services used in professional, medical, research, and industrial settings across the United States, China, and other international markets. The company reports operations through three segments: Biotechnology, Life Sciences, and Diagnostics. Its portfolio includes tools and consumables for therapeutic development and manufacturing, instruments and reagents for scientific research, and clinical systems used to support disease diagnosis and treatment decisions. Danaher was incorporated in 1969, adopted its current name in 1984, and is headquartered in Washington, D.C.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-DHR
$204.54
18.3% Upside
Undervalued
$242.52
40.2% Upside
Undervalued
Good
June 26, 2026
July 31, 2026
1.6
0.8%
July 21, 2026
38.7x
2.7x
5.7x
142.3 B
156.3 B
12.1%
89.1%
7.8
24.7%
144.0%
Send a message
Valuation • Fair Value

Danaher Corporation (NYSE-DHR) Fair Value by Valuation Model

Compare the primary fair value estimate for Danaher Corporation (NYSE-DHR) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$204.54

Estimated upside of 18.3% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$206.15

Discounted cash flow valuation reference.

Ben Graham Formula Value

$57.61

Classic Ben Graham valuation formula reference.

DDM Fair Value

$189.47

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$207.96

Comparable-company valuation reference.

Analyst Price Target

$242.52

Analysts imply upside of 40.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Danaher Corporation (NYSE-DHR) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Danaher Corporation (NYSE-DHR)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

24.778 B

Current operating scale indicator.

Revenue Forecast

26.34 B

Forward revenue estimate.

EBITDA

7.935 B

Current operating profitability reference.

EBITDA Forecast

8.342 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Danaher Corporation (NYSE-DHR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Danaher Corporation (NYSE-DHR)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.59

No elevated caution signal from this screen.

Altman Z-Score

7.8

Relatively strong balance-sheet zone.

FCF / Net Income

144.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Danaher Corporation (NYSE-DHR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Danaher Corporation (NYSE-DHR)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 21, 2026

Days to Earnings

0

Dividend Payment Date

July 31, 2026

Ex-Dividend Date

June 26, 2026

Dividend Yield

0.8%

Income yield reference.

Upcoming Dividend

1.6

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

24.7%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Danaher Corporation (NYSE-DHR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Danaher Corporation (NYSE-DHR) Stock Forecast & Technical Outlook

Review Danaher Corporation (NYSE-DHR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Danaher Corporation (NYSE-DHR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Danaher Corporation (NYSE-DHR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Danaher Corporation (NYSE-DHR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Danaher Corporation (NYSE-DHR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Danaher Corporation (NYSE-DHR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Danaher Corporation (NYSE-DHR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Danaher Corporation (NYSE-DHR) has a Strong Buy consensus, with 17 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 17
Hold 4
Sell 0
FAQ • Fast Investor Answers

Danaher Corporation (NYSE-DHR) Stock FAQ

Quick answers about Danaher Corporation (NYSE-DHR) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$204.54
Estimated upside 18.3%
Valuation Rating
Undervalued
Estimated upside of 18.3%
Analyst Target
$242.52
Implied upside 40.2%
Financial Health
Good
Current financial-health read

The current fair value estimate for Danaher Corporation (NYSE-DHR) is $204.54. This implies an estimated upside of 18.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 18.3% versus the current market price.

The available analyst price target for Danaher Corporation (NYSE-DHR) is $242.52. The analyst target implies estimated upside of 40.2%.

The current financial health read for Danaher Corporation (NYSE-DHR) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Danaher Corporation (NYSE-DHR) is July 21, 2026.

Based on the current data, dividend yield is 0.8%, upcoming dividend amount is 1.6, ex-dividend date is June 26, 2026, payment date is July 31, 2026.

The current P/E ratio listed for Danaher Corporation (NYSE-DHR) is 38.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Danaher Corporation is 142.3 B.

The current enterprise value listed for Danaher Corporation is 156.3 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Danaher Corporation is NYSE-DHR, and the stock is listed on NYSE.

Danaher Corporation (NYSE-DHR) is listed on NYSE.

The current debt-to-total-capital ratio listed for Danaher Corporation is 12.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Danaher Corporation is 89.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NYSE View more

Thermo Fisher Scientific Inc (TMO) Thermo Fisher Scientific Inc (TMO)
Agilent Technologies Inc (A) Agilent Technologies Inc (A)
Waters Corporation (WAT) Waters Corporation (WAT)
IQVIA Holdings Inc (IQV) IQVIA Holdings Inc (IQV)
Mettler-Toledo International Inc (MTD) Mettler-Toledo International Inc (MTD)
West Pharmaceutical Services Inc (WST) West Pharmaceutical Services Inc (WST)
Revvity Inc (RVTY) Revvity Inc (RVTY)
Charles River Laboratories (CRL) Charles River Laboratories (CRL)
Qiagen NV (QGEN) Qiagen NV (QGEN)
Bio-Rad Laboratories B (BIOb) Bio-Rad Laboratories B (BIOb)
Bio-Rad Laboratories Inc (BIO) Bio-Rad Laboratories Inc (BIO)
Avantor Inc (AVTR) Avantor Inc (AVTR)
Stevanato Group SpA (STVN) Stevanato Group SpA (STVN)
Ginkgo Bioworks Holdings (DNA) Ginkgo Bioworks Holdings (DNA)